Kurome Therapeutics Announces Oral and Poster Presentations on Dual IRAK1/4 Inhibitors at American Society of Hematology Annual Meeting

ASH 2022 Presentation Details:

Oral Presentation Title: IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML
Presenter and Lead Author: Josh Bennett, BS, Cincinnati Children’s Hospital Medical Center, and Daniel T. Starczynowski, PhD, Cincinnati Children’s Hospital Medical Center
Session Name: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Immune Signaling and Antibody-therapeutic Targeting in Myeloid Neoplasms
Presentation Date/Time: Monday, December 12, 2022, at 4:30 p.m. CST
Location: Ernest N. Morial Convention Center, 353-355

Poster Presentation Title: Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML
Publication Number: 2647
Authors: Jan S Rosenbaum, PhD, Kurome Therapeutics, Scott B. Hoyt, Ph.D., National Center for Advancing Translational Sciences, National Institutes of Health, Amal S. Kolt, MS, Kurome Therapeutics, Daniel A Luedtke, PhD, Kurome Therapeutics, Craig J. Thomas, PhD, National Center for Advancing Translational Sciences, National Institutes of Health, and Daniel T. Starczynowski, PhD, Cincinnati Children’s Hospital Medical Center
Session Name: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Session Date/Time: Sunday, December 11, 2022, 6:00 - 8:00 p.m. CST
Location: Ernest N. Morial Convention Center, Hall D

Abstracts are available on the ASH meeting website at www.hematology.org

About Kurome Therapeutics

Kurome® Therapeutics is a late-stage preclinical company focused on targeting innate immune signaling pathways in cancer. Kurome is developing a series of potent IRAK1/4 and panFLT3 inhibitors that work by targeting key cancer survival pathways. The company’s first to market indications will be Acute Myeloid Leukemia (AML) and high-risk MDS. Kurome is also developing a companion diagnostic and biomarker program.

Please find more information at www.kurometherapeutics.com

NOTE: Daniel Starczynowks’s disclosures pertaining to Kurome Therapeutics include: Consultancy, Current holder of stock options in a privately-held company, Membership on an entity’s Board of Directors or advisory committees, Patents & Royalties, Research Funding

View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005474/en/